COVID-19 Records

Gates Package — page 42

of 1375 pages

← p.41 p.43 → · this page in the original PDF · package

www.cbrintl.com<http://www.cbrintl.com><https://email.healthsystem.virginia.edu/owa/UriBlockedError.aspx><http:/ /www.cbrintl.com/> This electronic transmission (including any and all attachments) is intended solely for the use of the individual or entity to whom it is addressed and may contain information that is privileged and/or confidential. If you are not the intended recipient of this electronic transmission, you are hereby notified that any disclosure, copying or distribution, or the taking of any action in reliance upon the contents of this electronic transmission, is strictly prohibited, and you are further requested to purge this electronic transmission and all copies thereof from your computer system. From: Marshall Hoke Sent: Wednesday, July 30, 2014 11:25 AM To: 'Larry Zeitlin'; Trina Racine; deborah scott Cc: Frederick G *HS Hayden; Gary (Public Health Agency of Canada) Kobinger; HR © 1 ih. gov< mailto IO nih. gov><mailto {MH nih.gov> [C] Olinger; Peter (NIH/NIAID) [E] Jahrlin, ike Hensley; Lisa (NIH/NIAID) [E] Hensley; Miles Brennan; Tara Nyhuis Subject: RE: Combining the existing Phase 1 with a Therapeutic Portion Dear All, At the request of Dr. Zeitlin in the email below, we would like to propose a teleconference this Friday (8/1/2014) at 7 AM PDT/ 8 AM MDT/ 9 AM CDT/ 4 PM CEST. Alternatively, we would propose a teleconference next Tuesday (8/5/2014) at 7 AM PDT/ 8 AM MDT/ 9 AM CDT/ 4 PM CEST if Friday is not an option for the group. Please let us know your availability and we will draft a preliminary agenda and distribute it to everyone along with dial-in information. Thank you, Marshall Marshall Hoke, B.A. Technical Associate CBR International Corp. (r) www.cbrintl.com<http://www.cbrintl.com><https://email.healthsystem.virginia.edu/owa/UrlBlockedError.aspx><http:/ /www.cbrintl.com/> This electronic transmission (including any and all attachments) is intended solely for the use of the individual or entity to whom it is addressed and may contain information that is privileged and/or confidential. If you are not the intended recipient of this electronic transmission, you are hereby notified that any disclosure, copying or distribution, or the taking of any action in reliance upon the contents of this electronic transmission, is strictly prohibited, and you are further requested to purge this electronic transmission and all copies thereof from your computer system. From: Larry Zeitlin [mailto {© mappbio.com] Sent: Wednesday, July 30, 2014 10:55 AM To: Trina Racine; deborah scott Cc: Frederick G *HS Hayden; Gary (Public Health Agency of Canada) Kobinger; HR © 1b. cov< mailto FO nin.gov><mailto FO nih.gov> [C] Olinger; Peter (NIH/NIAID) [E] Jahrling; Mike Hensley; Lisa (NIH/NIAID) [E] Hensley; Miles Brennan; Tara Nyhuis; Marshall Hoke Subject: Re: Combining the existing Phase 1 with a Therapeutic Portion Hi all,

This is our OCR of the page, with running headers and footers removed. The Committee's PDF is authoritative; quote from it. Machine-readable, including the uncleaned text: /api/page/gates/42

Records on this page

RecordDateTypePages
gates:email:00012 2014-07-30 email 42–43
RE: Combining the existing Phase 1 with a Therapeutic Portion 2014-08-03 email 40–42